Literature DB >> 32266961

NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy.

Lingyun Wu1, Xiao Li1, Feng Xu1, Dong Wu1, Qi He1, Luxi Song1, Chao Xiao1, Youshan Zhao1, Zheng Zhang1, Juan Guo1, Liyu Zhou1, Jiying Su1, Chunkang Chang1.   

Abstract

Entities:  

Keywords:  DNMT3A; decitabine; mutation; myelodysplastic syndrome; nucleophosmin-1

Year:  2020        PMID： 32266961     DOI： 10.1111/bjh.16628

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

Review 1.  NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors:  Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

2.  Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.

Authors:  Xiao Li; Feng Xu; Zheng Zhang; Juan Guo; Qi He; Lu-Xi Song; Dong Wu; Li-Yu Zhou; Ji-Ying Su; Chao Xiao; Chun-Kang Chang; Ling-Yun Wu
Journal:  Clin Epigenetics       Date:  2021-08-30       Impact factor: 6.551

Review 3.  The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms.

Authors:  Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-01-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.